
Liberum Bio
Doing for pathway engineering what the desktop printer did for 'zines.
- Founded
- 2020
- Employees*
- 1-10
- Funding to Date*
- undisclosed
- Website
- liberumbio.com
While Twist and Illumina dominate the DNA sequencing and synthesis markets, there is still a bottleneck in recombinant protein production. We want to fill that void.
By 2025, the recombinant protein market is expected to reach $400 billion.
Today, to produce any sort of custom recombinant protein, it takes weeks. This dramatically slows down scientists’ ability to test, iterate, and improve. Liberum’s affordable, benchtop protein printer will cut that time down to a few hours.